GLP-1 receptor agonists like semaglutide and tirzepatide have become central to weight management and metabolic health conversations. As demand has outpaced supply, compounded versions of these medications have entered the telehealth market. Understanding the difference between compounded and branded GLP-1s — and the regulatory frameworks governing each — is essential for anyone considering these therapies.

Medical Disclaimer

The information in this article is for general education only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider before starting, stopping, or changing any medication. ZYNDIO connects adults with licensed providers via telehealth; the providers — not ZYNDIO — make all clinical decisions. Compounded medications dispensed through ZYNDIO partners are not FDA-approved drug products. They are prepared by state-licensed compounding pharmacies pursuant to a valid prescription. Individual results vary. Side effects, drug interactions, and contraindications exist for every therapy discussed here.

What GLP-1 Receptor Agonists Are

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications that mimic a naturally occurring hormone involved in blood sugar regulation and appetite control. When administered, these drugs bind to GLP-1 receptors in the pancreas, gut, and brain, triggering several effects: increased insulin secretion in response to meals, decreased glucagon release, slowed gastric emptying, and reduced appetite signaling in the hypothalamus.

Semaglutide and tirzepatide are the two most widely discussed molecules in this category for weight management. Semaglutide is a pure GLP-1 receptor agonist. Tirzepatide is a dual agonist, activating both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, which may enhance metabolic effects.

A 2021 trial published in The New England Journal of Medicine (PMID: 33567185) followed 1,961 adults without diabetes who received semaglutide 2.4 mg weekly for 68 weeks. Participants experienced an average weight reduction of 14.9% from baseline, compared to 2.4% in the placebo group. A 2022 study in the same journal (PMID: 35658024) reported that tirzepatide 15 mg weekly resulted in an average weight loss of 20.9% over 72 weeks in adults with obesity.

These results established GLP-1 receptor agonists as among the most effective pharmacologic interventions for weight management studied to date.

Branded GLP-1 Products: Ozempic, Wegovy, Mounjaro, Zepbound

Branded GLP-1 medications are manufactured by pharmaceutical companies and have undergone the FDA's New Drug Application (NDA) review process. Each product carries specific labeled indications:

  • Ozempic (semaglutide): The FDA approved this formulation in 2017 for type 2 diabetes management at doses up to 2 mg weekly. It is not labeled for weight loss.
  • Wegovy (semaglutide): The FDA approved this higher-dose formulation (2.4 mg weekly) in 2021 specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition.
  • Mounjaro (tirzepatide): The FDA approved this dual agonist in 2022 for type 2 diabetes at doses up to 15 mg weekly.
  • Zepbound (tirzepatide): The FDA approved this formulation in 2023 for chronic weight management at the same dose range as Mounjaro.

Each branded product is manufactured under current Good Manufacturing Practice (cGMP) standards, with batch testing, stability data, and post-market surveillance required by the FDA. The prescribing information for each product includes detailed pharmacokinetics, contraindications, boxed warnings (such as thyroid C-cell tumor risk observed in rodent studies), and adverse event profiles drawn from phase 3 clinical trials.

What Compounded GLP-1 Preparations Are

Compounded medications are patient-specific preparations made by state-licensed compounding pharmacies. Compounded semaglutide and tirzepatide are not FDA-approved drug products. They are created by combining active pharmaceutical ingredients (APIs) sourced from FDA-registered suppliers with sterile diluents, preservatives, and excipients, then dispensed in vials or prefilled syringes pursuant to a valid prescription from a licensed provider.

Compounding is legal under two federal frameworks:

  • 503A pharmacies compound medications for individual patients based on a provider's prescription. These pharmacies operate under state pharmacy board oversight and are exempt from FDA premarket approval requirements when certain conditions are met.
  • 503B outsourcing facilities are federally registered and can compound larger batches without individual prescriptions, but they must register with the FDA, report adverse events, and undergo FDA inspections.

Compounded GLP-1 preparations do not undergo the same multi-phase clinical trial process, FDA review, or post-market surveillance as branded products. The FDA does not verify their safety, efficacy, or quality before they reach patients. Quality standards depend on the compounding pharmacy's adherence to USP <797> sterile compounding guidelines and state board regulations.

When Compounding Is Permitted: The FDA Shortage Framework

The FDA generally expects patients to use approved drug products when available. However, compounding is permitted under specific circumstances, one of which is drug shortage.

Both semaglutide and tirzepatide have appeared on the FDA's drug shortage list at various times since 2022 due to manufacturing capacity constraints and surging demand. When a drug is listed as in shortage, compounding pharmacies are allowed to prepare compounded versions without violating the Federal Food, Drug, and Cosmetic Act's restrictions on compounding copies of commercially available drugs.

As of early 2024, the FDA removed tirzepatide from the shortage list, then reinstated it following legal challenges and updated supply assessments. Semaglutide's shortage status has fluctuated similarly. Patients considering compounded GLP-1 therapy should verify current shortage status on the FDA's drug shortage database (https://www.accessdata.fda.gov/scripts/drugshortages/) and discuss implications with their provider.

A 2024 perspective in The New England Journal of Medicine (PMID: 38657663) examined the proliferation of compounded semaglutide and raised concerns about variability in potency, sterility lapses, and the lack of pharmacovigilance infrastructure compared to branded products. The authors emphasized that while compounding serves a legitimate need during shortages, patients and providers must perform heightened due diligence on pharmacy sourcing and testing.

Supply-Chain Transparency: What to Ask Your Telehealth Pharmacy

Because compounded medications are not subject to FDA premarket review, patients bear more responsibility for evaluating the quality and safety of the product they receive. ZYNDIO partners only with state-licensed compounding pharmacies that meet rigorous internal standards, but patients should understand what questions to ask any telehealth pharmacy:

  1. Is the pharmacy state-licensed and in good standing? Verify licensure with the state board of pharmacy where the pharmacy is located.
  2. Is the pharmacy 503A or 503B? 503B facilities are federally registered and inspected by the FDA; 503A pharmacies are state-regulated only.
  3. Where does the active pharmaceutical ingredient (API) come from? The API should be sourced from an FDA-registered facility. Ask if the pharmacy can provide a certificate of analysis (COA) from the supplier.
  4. Does the pharmacy perform sterility and potency testing? Reputable compounders send samples to third-party labs for endotoxin testing, sterility confirmation, and potency assays (HPLC or mass spectrometry).
  5. What preservatives and excipients are used? Some compounded formulations use benzyl alcohol as a preservative; others do not. This affects shelf life and injection site reactions.
  6. How is the product labeled? The vial or syringe should include the drug name, strength, lot number, expiration date, storage instructions, and pharmacy contact information.
  7. Is there a pharmacist available to answer questions? Access to a licensed pharmacist is a minimum standard for any compounding pharmacy.

ZYNDIO requires partner pharmacies to meet or exceed USP <797> sterile compounding standards, maintain active state licenses, source APIs from FDA-registered suppliers, and make potency and sterility testing results available on request. These measures do not eliminate all risk, but they reduce it substantially compared to unregulated sources.

Why ZYNDIO Ships Only From State-Licensed Pharmacies

The telehealth pharmacy market includes actors operating in legal gray zones: unlicensed entities shipping from overseas, vendors selling APIs directly to consumers for self-compounding, and "research chemical" suppliers marketing peptides labeled "not for human use" while implicitly promoting off-label injection. These channels carry serious safety risks, including contamination, incorrect dosing, and lack of medical oversight.

ZYNDIO's model is built around the legal and ethical standard for compounded medication dispensing: every prescription is written by a U.S.-licensed provider after a telehealth consultation, and every medication is dispensed by a state-licensed compounding pharmacy operating in compliance with state and federal law. This structure ensures:

  • A licensed provider evaluates your medical history, current medications, contraindications, and treatment goals before prescribing.
  • The pharmacy verifies the prescription, prepares the medication under sterile conditions, labels it appropriately, and ships it in compliance with pharmacy board regulations.
  • You have recourse if something goes wrong: a licensed pharmacist to call, a state board to file a complaint with, and a provider to report adverse events to.

No system is perfect, but this framework is the minimum standard for responsible telehealth pharmacy practice.

Risks, Side Effects, and Monitoring

Whether using a branded or compounded GLP-1 medication, the pharmacologic risks are similar because the active molecule is the same. Common side effects include:

  • Nausea, vomiting, diarrhea, constipation (most frequent; often dose-dependent and transient)
  • Abdominal pain or discomfort
  • Injection site reactions
  • Fatigue or dizziness

Serious risks, though less common, include:

  • Pancreatitis (symptoms: severe abdominal pain radiating to the back, nausea, vomiting)
  • Gallbladder disease (cholelithiasis, cholecystitis)
  • Hypoglycemia, especially if used with insulin or sulfonylureas
  • Acute kidney injury, often secondary to dehydration from GI side effects
  • Thyroid C-cell tumors (observed in rodent studies; relevance to humans unclear; contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2)

Compounded formulations introduce additional variables: potency variability, sterility risk if compounding practices are substandard, and the possibility of incorrect dosing if vial labeling is unclear. A provider should assess baseline labs (comprehensive metabolic panel, lipase if indicated, TSH) and monitor response and side effects during treatment.

When to Talk to Your Provider

You should consult a licensed healthcare provider before starting any GLP-1 therapy, whether branded or compounded. Specific scenarios requiring provider evaluation include:

  • You have a personal or family history of thyroid cancer, pancreatitis, or severe GI disease.
  • You are currently taking insulin, sulfonylureas, or other medications that affect blood sugar.
  • You are pregnant, breastfeeding, or planning to become pregnant (GLP-1 agonists are not recommended during pregnancy).
  • You experience severe or persistent side effects (severe abdominal pain, signs of pancreatitis, dehydration, allergic reaction).
  • You are considering switching from a branded product to a compounded version, or vice versa. Dose equivalence and formulation differences should be discussed.

A provider consultation via ZYNDIO or another telehealth platform is not a substitute for ongoing primary care. If you have complex medical conditions or take multiple medications, coordinate GLP-1 therapy with your primary care physician or endocrinologist.

FAQ

Is compounded semaglutide the same as Ozempic or Wegovy?

No. Compounded semaglutide contains the same active molecule as Ozempic and Wegovy, but it is not FDA-approved. It is prepared by a compounding pharmacy rather than a pharmaceutical manufacturer. Compounded semaglutide may differ in formulation, preservatives, potency, and sterility assurance depending on the pharmacy's practices.

Can I use compounded GLP-1 if the branded version is not on shortage?

Legally, compounding a copy of a commercially available drug when no shortage exists is restricted under federal law. If semaglutide or tirzepatide is removed from the FDA shortage list and adequate supply of the branded product is available, compounding may not be permitted. Verify current shortage status and discuss with your provider.

How do I know if my compounded GLP-1 is safe?

Verify that the dispensing pharmacy is state-licensed, ask for the API's certificate of analysis, confirm that sterility and potency testing are performed, and check that the product is labeled with lot number, expiration, and storage instructions. If the pharmacy cannot or will not provide this information, do not use the product.

Does insurance cover compounded GLP-1?

Most insurance plans do not cover compounded medications. Patients typically pay out of pocket. ZYNDIO's pricing structure is designed to make compounded therapies accessible when branded options are unavailable or unaffordable, but cost varies by dose and pharmacy partner.

What should I do if I experience side effects?

Contact your prescribing provider immediately if you have severe abdominal pain, persistent vomiting, signs of an allergic reaction (rash, swelling, difficulty breathing), or any symptom that concerns you. For mild side effects like nausea, your provider may adjust the dose or recommend supportive measures. Report adverse events to your provider and, if relevant, to the FDA's MedWatch program.

The Bottom Line

Branded GLP-1 products like Wegovy and Zepbound undergo rigorous FDA review and are manufactured under federal oversight. Compounded semaglutide and tirzepatide are not FDA-approved drug products but serve a legal and clinically appropriate role during drug shortages when dispensed by reputable, state-licensed pharmacies under valid prescriptions.

Patients considering compounded GLP-1 therapy should verify pharmacy credentials, ask for supply-chain transparency, and work with a licensed provider to assess candidacy, monitor response, and manage side effects. ZYNDIO's commitment to partnering only with state-licensed compounding pharmacies is a safeguard, but patient vigilance and provider communication remain essential.

Last reviewed: 2026-04-25 by ZYNDIO Clinical Editorial Team (PharmD-led)